APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

0.27

+0.01 (+4.25%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	0.26
Open	0.26
Bid	0.20 x 600
Ask	0.33 x 500
Day's Range	0.26 - 0.28
52 Week Range	0.25 - 3.34
Volume	396,410
Avg. Volume	1,590,161

Market Cap	6.329M
Beta	0.69
PE Ratio (TTM)	10.00
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire8 days ago
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...
GlobeNewswire8 days ago
Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
FDA Confirms Vitaros Regulatory Pathway. Company Seeking Partner to Develop Vitaros in U.S.. SAN DIEGO, April 16, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines ...
GlobeNewswire20 days ago
Apricus Biosciences Announces Closing of $3.55 Million Public Offering
SAN DIEGO, April 04, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its previously announced public ...
GlobeNewswire27 days ago
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...
GlobeNewswire27 days ago
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
SAN DIEGO, March 28, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has priced a public offering of an ...
GlobeNewswire28 days ago
Apricus Biosciences Announces Proposed Public Offering
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...
GlobeNewswire28 days ago
Apricus Biosciences Announces Proposed Public Offering
SAN DIEGO, March 27, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of ...
GlobeNewswire29 days ago
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, ...
GlobeNewswire29 days ago
Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA
SAN DIEGO, March 26, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. ...
ACCESSWIRElast month
Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
ACCESSWIRElast month
Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash
Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...
GlobeNewswire2 months ago
Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call / Webcast ...
GlobeNewswire2 months ago
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
Company Expects to Submit Vitaros End of Review Meeting Request This Month. Vitaros End-of-Review Meeting Expected to Occur in April 2018. Company Expects Cash Runway Through 2018.
ACCESSWIRE2 months ago
Apricus Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Apricus Biosciences, Inc. (NASDAQ: APRI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 4:30 PM Eastern ...
GlobeNewswire2 months ago
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company`s ...
GlobeNewswire2 months ago
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
SAN DIEGO, Feb. 21, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full ...
GlobeNewswire2 months ago
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)
Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines ...
GlobeNewswire2 months ago
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
SAN DIEGO, Feb. 16, 2018-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ...
ACCESSWIRE6 months ago
SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...
GlobeNewswire6 months ago
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus` ...
GlobeNewswire6 months ago
Apricus Biosciences to Present at the 2017 BIO Investor Forum
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard ...
ACCESSWIRE7 months ago
SeeThruEquity Issues Company Update on Apricus Biosciences (NASDAQ:APRI) with Target Price of $4.30
NEW YORK, NY / ACCESSWIRE / October 3, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has ...